ABC-DLBCL	Activated B cell DLBCL
ACT	Adoptive cell therapy
ADC	Antibody-drug conjugate
ADCC	Antibody-dependent cellular cytotoxicity
APC	Antigen presenting cell
BCL2	B cell lymphoma 2
BCR	B cell receptor
bFGF	Basic fibroblast growth factor
BTK	Bruton tyrosine kinase
CDK	Cyclin-dependent kinase
CELMoD	Cereblon E3 ligase modulator
CLL	Chronic lymphocytic leukemia
CORO1B	Coronin 1B
CR	Complete response
CRBN	Cereblon
DC	Dendritic cell
DLBCL	Diffuse large B cell lymphoma
EC	Endothelial cell
EMA	European Medicines Agency
FDA	Food and Drug Administration
FDC	Follicular Dendritic Cell
FL	Follicular lymphoma
GAB1	GRB-2 associated binding protein 1
GCB-DLBCL	Germinal center B cell DLBCL
ICB	Immune checkpoint blockade
IFN	Interferon
IHC	Immunohistochemistry
IKZF1	Ikaros
IKZF3	Aiolos
IL-2	Interleukin-2
IMiDs	Immunomodulatory Drugs
IRF4	Interferon regulating factor 4
mAb	Monoclonal antibody
MCL	Mantle cell lymphoma
MDS	Myelodysplastic Syndrome
MM	Multiple Myeloma
MOA	Mechanism of action
MOR-28	Tafasitamab
MSC	Mesenchymal stem cells
MZL	Mantle zone lymphoma
NF-kB	Nuclear factor kB
NHL	Non-Hodgkin Lymphoma
NK	Natural killer
NLC	Nurse-like Cell
ORR	Overall response rate
OS	Overall survival
PFS	Progression free survival
R/R	Relapsed and/or Refractory
R2	Rituximab plus lenalidomide
TAM	Tumor-associated macrophage
TFH	T follicular helper cells
TME	Tumor microenvironment
Treg	Regulatory T cells
VEGF	Vascular endothelial growth factor